Skip to content

Design Therapeutics, Inc. DSGN Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$839.42M+295%
Enterprise value$829.39M+313%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Design Therapeutics, Inc.'s capital investments accrued but not yet paid?
Design Therapeutics, Inc. (DSGN) reported capital investments accrued but not yet paid of $0 in Q1 2026.
How has Design Therapeutics, Inc.'s capital investments accrued but not yet paid changed year-over-year?
Design Therapeutics, Inc.'s capital investments accrued but not yet paid decreased by 100.0% year-over-year, from $54K to $0.